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The 10-90 gap is an idea in the healthcare literature that less than 10% of all research
funding goes to solving health problems that are 90% of the global disease burden.
This paper examines whether there is inequality in nanotechnology healthcare
research (nanomedicine). To understand the inequality in nanomedicine, I conducted
a bibliometric review of Web of Science and PubMed databases. Overall there is
not large inequality in nanomedicine research. The bibliometric analysis shows
that most nanomedicine research is done in high income countries, but their
research portfolios extend beyond rich world diseases like Alzheimer’s disease and
diabetes to include research on malaria, tuberculosis and HIV/AIDS. Of the
nanomedicine articles that are directed towards specific diseases (about 20% in
Web of Science and PubMed), the majority of the research (86%) will help both the
rich and the poor, while only 7% of the research focuses solely on rich world diseases
and 7% focus solely on diseases of poverty. The most researched nanomedicine
topic is cancer. It accounts for 16% of nanomedicine literature. Overall less than
20% of nanomedicine research goes to solving health problems that are 50% of
the global disease burden. Given nanotechnology is so linked to chemistry and the
chemicals industry, the inequality within nanomedicine will impact how those
industries supply materials, supplies and information to the various stakeholders
involved in nanotechnology and healthcare.
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of HIV/AIDS. It’s estimated that HIV/AIDS is the
6th most deadly disease and that the disease
kills 2 million people each year (World Health
Organization, 2008).
Despite efforts to improve the health of the
indigent, the poor live a greater proportion of
their lives sick compared to the rich and they
have significantly lower life expectancy than
the rich (World Health Organization, 2008). A
potential cause of the health disparity is that
there is not much research on diseases that
affect the poor. The Global Forum for Health
Research came up with the term the 10/90 gap
to describe the inequalities in health research
funding (Global Forum for Health Research,
2004). The 10/90 gap refers to the phenomenon
that less than 10% of research funding goes to
studying diseases that are 90% of the disease
burden. Since 1990, the Global Forum for Health
Research has brought awareness to the 10/90
gap by producing reports that track research
disparity and engaging with the public and
1 Backround/Literature Review
Access to health care is a basic human right
and over the past twenty years healthcare has
become a focus of development and aid
organizations. One major initiative to improve
global health is the United Nations’ (UN)
Millennium Development Goals (MDGs) that
were adopted in 2000. The MDG’s outline eight
different poverty arenas that the world
community wants to alleviate by 2015 (United
Nations, 2010a). Three of the goals, child health,
maternal health, and HIV/AID, deal directly with
healthcare. With regards to child health, the
UN wants to reduce under five-child mortality
rate by two-thirds by focusing on decreasing
pneumonia, diarrhea and measles. For maternal
health, the MDG is to reduce the maternal
mortality ratio by three-quarters and ensure
that every woman has access to pre-and
postnatal care. Finally the world community has
committed to halting and reversing the spread
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medicines exist to treat these ailments.
Individuals die from these diseases because of
other societal factors that prevent treatment,
not from a lack of research. Finally the
opponents of the 10/90 problem state that many
organizations, like the Infectious Disease
Research Institute, study diseases of poverty
and hence there is not a dearth of research on
neglected diseases (Stevens, 2007).
This paper investigates the 10/90 gap in
relation to nanotechnology. Many believe that
nanotechnology is the next big research trend.
One scholar, Mohamed Hassan (2005), says that
“nanotechnology could prove to be a
‘transformative technology comparable in its
impact to the steam engine in the 18th century,
electricity in the 20th century, and the Internet
in contemporary society” (Hassan, 2005). As a
result many countries, especially poorer
countries, are heavily investing in the technology.
A study conducted by Salamanca-Buentello et
al. (2005) outlines ten different
nanotechnologies that will help the world’s poor.
Three of the ten technologies, disease diagnosis,
drug delivery, and health monitoring, deal with
healthcare issues (Salamanca-Buentello, 2005).
There is often confusion in defining
nanotechnology (Balogh, 2010). This paper uses
the National Nanotechnology Initiative
definition of nanotechnology which “is the
understanding and control of matter at
dimensions between approximately 1 and 100
nanometers, where unique phenomena enable
novel applications. Encompassing nanoscale
science, engineering, and technology,
nanotechnology involves imaging, measuring,
modeling, and manipulating matter at this
length scale” (PCAST, 2010). At the nanoscale,
matter has different properties, like conductivity
and reactivity, which make it possible to do novel
research and create new products. Central to
nanotechnology is chemistry. Chemistry
specializes in manipulating atoms and molecules
to create new substances (Whitesides, 2005).
Without chemistry, nanotechnology and hence
nanomedicine, could not exist as an emerging
technology.
It is estimated that in 2005 there were 38
nano-enabled medical products with sales of
about $6.8 billion, over 150 companies working
in nanomedicine. This market was expected to
double by 2012 (Wagner, Dullaart, Bock, & Zweck,
2006). In addition to these products, the field
of nanotechnology will have a variety of
economic impacts like increasing the
media about the problem. A report by the
Médecins Sans Frontières found that health
research expenditures are still heavily
imbalanced. Four major diseases in developing
countries tuberculosis, leishmaniasis, malaria,
and trypanosomiasis are 5% of the global disease
burden, but research expenditures for this
disease are 0.1% of global health R&D (Global
Forum for Health Research, 2004; Médecins Sans
Frontières, 2001). Other studies have discussed
the 10/90 gap in other healthcare arenas like
medicines(Reich, 2000), female healthcare
research (Doyal, 2004), cardiovascular diseases
research (Martini et al., 2003) and healthcare
publications (Mari et al., 2010; Pastrana et al.,
2010). In general these studies reach similar
conclusions as the Global Health Forum and
Médecins Sans Frontières; medicine and health
R&D is unequal and that society needs major
reforms to fix the problem.
Compared to income and education
inequality, health inequality is particular
dangerous because unlike other problem facing
society, diseases can easily jump borders and
spread around the world. Bacteria and infections
are not biased; they can infect the rich and poor,
global north and global south. In the past
century rich countries undertook vast campaigns
to eradicate several diseases like malaria and
mumps. However if the diseases are not treated
in other parts of the world, they could reemerge
in healthier nations. Recently The National
Institute of Allergy and Infectious Disease in
the USA identified five reemerging diseases
including the mumps virus, streptococcus (strep
throat), staphylococcus aureus (staph infection)
(NIH, 2010).
However the legitimacy of the 10/90 gap has
been challenged (Stevens, 2007). The opponents
of the 10/90 gap argue that the poor’s higher
mortality rates have little to do with research
portfolios, but rather other societal conditions
that prevent the poor from getting the necessary
treatment. The opponents cite that most
individuals in developing countries do not die
from obscure diseases, but rather from more
common illnesses like lower respiratory
infections and heart disease. These diseases
afflict both the rich and the poor (World Health
Organization, 2008) and hence it is an
exaggeration to say that 90% of all research
funding goes to solving problems of the rich.
Moreover critics note that other major killers of
the poor, like malaria and diarrheal diseases,
have been thoroughly studied and many
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income or low income countries. The currently
literature on the 10/90 gap supports the idea
that medical research will focus on diseases of
the rich. Moreover, much of the medical research
is funded by governments. Since the very high
income countries invest more in R&D than
medium and low income countries, it is expected
that most of the money will focus on problems
that affect those countries.
Hypothesis 2: There is a disproportionate
amount of nanotechnology research conducted
on diseases of very high income countries as
opposed to the diseases of other countries
A third factor of inequality is whether
researchers are focusing on the most dangerous
diseases or are their attentions drawn to diseases
that cause relatively few deaths. The literature
suggests that research is focused on diseases
that cause relatively few deaths while neglecting
diseases that cause a lot of deaths (Global Forum
for Health Research, 2004).
H1.3 The majority of nanomedicine research
will only address diseases that kill relatively
few people.
This study fills a gap in the literature. Most
other studies discuss the societal and ethical
implications (SEI) of nanotechnology and
describe potential problems that may arise
because of it (ETC Group 2006; Meridian
Institute, 2006; Roco & Bainbridge, 2005). But
there are few articles that quantitatively analyze
inequality in nanotechnology research. This
paper, on the other hand, examines the actually
trends in nanomedicine research to determine
if scientists are studying nanotechnology for
the poor. In addition, this study not only explores
where the research is being conducted, but it
analyzes the content of the publications to
determine which diseases are receiving the most
attention.
3 Methods
To analyze inequality in nanomedicine
research, I conducted a bibliometric examination
of Web of Science (WoS) and PubMed databases.
Web of Science is one of the largest publication
databases. It contains over 13,000 journals in
200 disciplines ranging from 1900 until today
(Thomson Reuters, 2012). WoS is a prominent
database used by bibliometricians (Leydesdorff,
productivity of manufacturing, create a bigger
market for scientists familiar with
nanotechnology, and increase competition
between sectors (Zawislak, Marques, Esteves, &
Rublescki, 2010). Chemistry and chemical
companies are also expected to benefit from
the increased emphasis on nanomedicine.
Chemical companies supply many of the
materials and equipment to conduct
nanomedicine research. Moreover chemists are
often used in nanotechnology labs to do
research. (Zawislak et al., 2010). Hence it is
important for chemists and chemical businesses
to understand nanomedicine in order to
participate in this new emerging field and
market.
2 Research Problem
Though there is some agreement that
nanotechnology can help the world’s poor, is
there poverty related nanotechnology research
being conducted or is all the research geared to
the problems of the rich and luxury goods? Is
the 10/90 gap strong in nanomedicine or is the
gap a different ratio? This study is a descriptive
investigation of research intensity in
nanomedicine and inequality in nanomedicine
research.
There are three factors of nanomedicine
inequality. First inequality in nanomedicine
occurs between the different income levels of
countries. Do very high income countries
dominate the research or is the research
occurring equally across the world? The global
distribution of nanomedicine is affected by two
competing trends. Scholars have observed that
nanotechnology research is taking place in both
rich and poor countries. Many poor countries
view nanotechnology as the next technology
revolution so they are investing in the field early
so they will not be left behind (Hassan, 2005).
As a result it is expected that nanomedicine
research will be done in low income countries.
However medical research is still dominated by
rich countries (Médecins Sans Frontières, 2001)
and therefore it is also likely that nanomedicine
will follow the same trend as general medical
research.
Hypothesis 1: Nanomedicine research is
predominantly conducted in very high income
countries
A second factor of inequality in nanomedicine
is whether it focuses on diseases of very high
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PubMed, a free online digital database of
biomedical journal articles developed by the
National Center for Biotechnology Information
in the U.S. PubMed is a smaller database than
WoS, but it is geared towards biomedical and
health care related articles. The major
component of PubMed is a database called
Medline which has about 5,400 journals dating
back to 1948 (National Center for Biotechnology
Information, 2012). After accessing PubMed, I
searched for nanotechnology articles in the
database using a similar version of the Porter
et al (2007) strategy. The PubMed search yielded
56,000 nanotechnology articles.
After the two nanotechnology databases
were created, I developed a search strategy to
find the health related articles by reading several
nanomedicine review articles (ETC Group, 2006;
OECD, 2005; Sahoo, Parveen, & Panda, 2007; Silva,
2004). These articles gave the keywords to
formulate the health filter. See Table 1 for the
2008) to study publication and collaboration
patterns in diverse topics like including tropical
medicine (Falagas, Karavasiou, & Bliziotis, 2006),
nano/biosensors (Huang, Peng, Guo, & Porter,
2010) and emerging technologies (S. Cozzens et
al., 2010). My analysis is based on a
nanotechnology database created by a group
of researchers at the Georgia Institute of
Technology (Porter, Youtie, Shapira, & Schoeneck,
2007). The database contains a list of all the
nanotechnology articles in WoS. The team
created the database by using eight Boolean
logical search phrases to find the
nanotechnology articles and then they used a
second list of keywords to remove extraneous
articles from their search. The database contains
articles ranging from 1990-2012, but this study
limits its scope to nanotechnology publications
from 2000-2010. From 2000-2010, there are
about 617,000 nanotechnology articles.
The second database used in this study is
Table 1 Health search keywords
- alzheimer
alzheimer [a-z]*
- cardiovascular - pregnant- hepatitis
- biomedical
biomedic[a-z]*
biocomp[a-z]*
- blood
- Bone
dentin
skull
bones
skelet[a-z]*
- brain
nervous syst[a-z]*
brain[a-z]*
neuron
- cancer
chemother[a-z]*
mamap[a-z]*
cancer
breast
mammogr[a-z]*
tumor
antitumor
- cholesterol
- clinical
clinic[a-z]*
- dental
- diabetes
- disease
- drug
- health
dental[a-z]*
^peridonta[a-z]*
diabetes[a-z]*
insulin
diseas[a-z]*
pathogen
drug delivery
vaccine
antibiotic
drug[a-z]*
health[a-z]*
- humans
- liver
- malaria
- medical
- medicine
- orthopedic
- pediatric
- pharma
- psychotic
- sick
- skin
- therapeutic
- tissue
- toxicity
- tuberculosis
hepatitis[a-z]*
male
human[a-z]*
female
^liver$
medic[a-z]*
physio[a-z]*
nanomedi[a-z]*
medicin[a-z]*
orthoped[a-z]*
prosthetic
pharma[a-z]*
pregnan[a-z]*
psychotic[a-z]*
psycholo[a-z]*
dopamine
illness
therap[a-z]*
tissue
engineering
tissue
toxin[a-z]*
toxic[a-z]*
absent from the study. 
The 10/90 gap refers to the observation in
the 1990’s that less than 10% of research funding
went towards researching health problems that
account for 90% of the global disease burden
(Global Forum for Health Research, 2004).  For
this study, the global disease burden was based
the mortality rates of the top diseases around
the world.  In 2008 the World Health
Organization (WHO) updated a 2004 study that
measured the top diseases based on their
mortality rates. The WHO also classified the
diseases based on a variety of factors including
list of keywords. Out of the 617,000
nanotechnology articles in WoS, 12% relate to
nanomedicine; in PubMed, 48% of the 118,000
nanotechnology article relate to medicine.
Like all databases, WoS and PubMed have
their limitations.  These databases have a greater
representation of journals from rich, western
countries compared to developing countries and
these databases bias towards journals that are
in English (UNESCO, 2005).  Moreover the
databases do not have 100% coverage of all the
journals and so some publications that are not
indexed in Web of Science or PubMed will be
Rank
2
6
8
9
...
1
3
4
5
7
10
World
Ischaemic heart disease
Diarrhoel diseases
Tuberculosis
Trachea/bronchus/lung cancers
Prematurity/ low birth weight
Cerebrovascular disease
Lower respiratory infections
COPD
HIV/AIDS
Road traffic accidents
...
Total Deaths Worldwide
7.2
4.2
1.5
1.3
1.2
...
5.7
3.0
2.2
2.0
1.3
Deaths
58.8
(millions)
% of Total
12.2
3.7
2.5
2.3
2.0
Deaths
9.7
7.1
5.1
3.5
2.2
...
100
High-Income Countries
Ischaemic heart disease
COPD
Colon and rectum cancers
Diabetes Mellitus
Stomach Cancer
Cerebrovascular disease
Trachea/bronchus/lung cancers
Lower respiratory infections
Alzheimer/ other dementias
Breast Cancer
...
Total 
1.3
0.5
0.3
0.2
0.1
...
0.8
0.3
0.3
0.3
0.2
Deaths
8.1
(millions) countries
Ischaemic heart disease
Diarrhoel diseases
Tuberculosis
Neonatal infections
Malaria
Cerebrovascular disease
Lower respiratory infections
COPD
HIV/AIDS
Prematurity/ low birth weight
...
Total 
5.9
3.8
1.4
1.1
0.9
...
5.0
2.7
2.1
2.0
1.1
Deaths
50.7
(millions)
Low and middle income
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Table 2 Leading cause of death worldwide in 2004 (World Health Organization, 2008)
Table 3 Leading cause of death in high and low income countries in 2004 (World Health Organization, 2008)
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the mortality rates of the diseases in high, middle
and low income countries (World Health
Organization, 2008).  Table 2 shows that top ten
causes of death worldwide and Table 3 shows
the top diseases in high and low income
countries income countries.  The leading causes
of death in the rich world come from illnesses
like Alzheimer’s disease, lung, colon, breast and
stomach cancers, and diabetes.  In poor countries,
a large percent of the population die from
diarrheal diseases, HIV/AIDS, tuberculosis and
malaria. There are four diseases, ischaemic heart
diseases, cerebrovascular disease, lower
respiratory infection and COPD, that are common
in both high income and low income countries.
The list of diseases from the World Health
Organization’s Burden of Disease report was
used to develop a search filter to find diseases
in the nanomedicine database and to classify
the diseases as high income or low income
country diseases (World Health Organization,
2008). 
Finally this study classifies countries using
the 2011 United Nations Human Development
Index (UN-HDI). The UN-HDI groups countries
into four categories, very high development,
high development, medium development and
low development, by using three dimensions,
health, education levels, and living standards to
develop a composite measure of the countries
and then ranks them (United Nations, 2010b).
4 Results
4.1 Data Description
Below is the summary data from the
nanomedicine database.  WoS contains 77,078
nanomedicine articles and PubMed contains
63,653 nanomedicine articles from 2000-2010.
In those 11 years both PubMed and WoS had a
steady increase in the number of nanomedicine
articles.  However the databases contain
different relative amounts of nanomedicine
publications (see right axis of Figure 1). In
PubMed more than 50% of the nanotechnology
articles relate to nanomedicine while in WoS
between 10% and 20% of nanotechnology
articles relate to nanomedicine. It’s not surprising
that PubMed has relatively more nanomedicine
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Figure 1 Web of Science and PubMed publications by year
2000
4000
Ratio Deaths to articles (PubMed)
PubMed nanomedicine
% nanomed. Articles WoS
% nanomed. Articles PubMed
article compared to WoS because the database
focuses on biomedical journals.  The percent of
nanomedicine articles in WoS increase from 10%
to 20% from 2000 to 2010. In 2000, 70% of
nanotechnology articles in PubMed related to
nanomedicine.  However by 2005 the percent
of nanomedicine articles in PubMed fell to 50%.
4.2 Country level inequality
Table 4 is a list of the top countries publishing
nanomedicine articles.  In general, very high
income countries like the USA, Germany, UK, and
Japan published the most nanomedicine articles.
However there are several emerging economies
that also publish a lot of nanomedicine research.
Most notably, China and India rank within the
top ten countries for nanomedicine publications.
In both the PubMed and Web of Science, China
has the second most nanomedicine publications.
China’s prominence in nanomedicine research
is not unexpected. It is estimated that China
spent over $250 million on nanotechnology in
2008 (Liu et al., 2009) and that it has over 30
institutions conducting nanotechnology research
(Niosi & Reid, 2007).  Moreover, other studies
have also confirmed that China is a world leader
in nanotechnology (Guan & Ma, 2007; Liu et al.,
2009).  India ranks tenth in nanomedicine
publications in WoS and seventh in PubMed.
Since 2001, India has formally invested in
nanotechnology.  In 2007 India started the
NanoMission and they committed US $230
million to nanotechnology (Ramani, Chowdhury,
Roger, & Reid, 2010). Other emerging economies
like Brazil, Russia, Turkey and Iran rank within
Rank
2
6
8
9
...
1
3
4
5
7
10
USA
Germany
S. Korea
India
Canadia
...
China
Japan
UK
France
Italy
Brazil
Country
24400
6000
3600
2900
2400
...
12500
5200
4600
3900
3000
1300
WoS
17200
3500
1400
2000
1600
...
7900
3700
3700
1900
2400
1200
PubMed
Country Classification
Very High Development
High Development
Medium Development
Low Development
71500
16300
5500
100
WoS
76.6%
17.5%
5.9%
0.1%
% Nanomedicine
WoS
46900
10500
3200
100
PubMed
77.3%
17.3%
5.3%
0.2%
% Nanomedicine
PubMed
...
16
19
... ... ...
Russia 1000 200
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Table 4 Nanomedicine publications by country
Table 5 Nanomedicine publications by country classification
* Note: articles co-authored by scientists in different country classifications are double-counted. Therefore if
someone from a very high development country works with someone from a low development country, the article is
counted in both categories.
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the top 25 nanomedicine publications in WoS
or PubMed.
Table 5 classifies the countries based on the
2011 United Nations Human Development Index.
There is a clear research gap between the
different country classifications.  The majority
of nanomedicine research is conducted in very
high income countries (about 77%) while the
high, medium and low income countries lag
behind. Medium development countries have
the second highest nanomedicine publication
count followed by high and low development
countries.   The productivity of medium countries
is led by China and India which are classified as
medium developed countries. 
4.3 Disease research inequality
Nanomedicine, like other scientific fields,
contains both basic and applied research.  Much
of the current literature in nanomedicine is basic
research and does not apply to a specific disease.
Using the top diseases found in the World Health
Organizations Burden of Disease report as a
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Disease
heart disease
cerebrovascular dis.
lower respiratory dis.
prematurity/neonatal infect.
8923
4177
5712
3180
(1000’s)
420
170
100
80
Deaths in 
2004
(WoS)
1000
620
230
630
(PubMed) Disease
X
Disease
X
X
X
Disease
COPD 3025 60 130 X
diarrhea
HIV/AIDS
tuberculosis
lung cancer
2163
1464
2040
1323
60
270
420
480
110
180
300
290 X
X
X
X
traffic accidents 1275 0 0 X
diabetes
malaria
self inflicted wounds
stomach cancer
1141
844
890
803
290
0
170
10
940
0
150
10
X
X
X
psychological dis. * 661 640 670 X X
colon cancer
breast cancer
Alzheimer
prostate cancer
639
492
519
308
220
820
1630
570
210
430
750
310
X
X
X
X
hepatitis (B and C) 159 530 320 X
arthritis
Parkinson’s
skin cancer
...
127
68
110
...
300
490
300
...
340
350
210
...
X
X
X
Total 58,772 16,550 12,880
Nano-
medicine
High and Low
IncomePublica-tions
Nano-
medicine
Publica-
tions
High
Income
Low
Income
* psychological diseases does not include Alzheimer’s disease or Parkinson’s disease
Table 6 Most researched diseases using nanomedicine in WoS and PubMed
cancers with the most publications, like breast
cancer, also have the most funding by the NCI. 
Another reason cancer features prominently
in nanomedicine is that scientists are
investigating whether nanoparticles cause
cancer. Some scientists worry that nanoscale
fibers like carbon nanotubes may increase the
risk of some types of cancer, like lung cancer, if
the particles are inhaled (Stern & McNeil, 2008).
Environmental, health and safety (EHS) research
of nanotechnology has grown in prominence
and funding over the past 10 years(National
Science and Technology Council, 2011)  and the
increasing emphasis on the EHS aspects of
nanotechnology may increase the nanomedicine
research on cancer.
Two main uses of nanomedicine for cancer
treatment are drug delivery systems and cancer
detection systems (Nie, Xing, Kim, & Simons,
2007).  Scientists are inventing better drug
delivery systems in order to target cancerous
cells more directly.  If the scientists can improve
drug delivery systems, they can increase the
effectiveness of the drugs and decrease the side
effects of cancer treatment. For cancer detection,
scientists hope that nanotechnology will enable
early detection of the cancerous cells so that
the disease can be treated earlier in its
development which will reduce the mortality
rate of cancers (Ferrari, 2005).  
Alzheimer’s, the second most researched topic
in WoS, is the 6th most common cause of death
for developed countries. Like cancer there is
significant funding and advocacy to support
Alzheimer’s research (Alzheimer’s Association,
2012). But unlike cancer Alzheimer’s is not one
of the top ten causes of death.  Rather,
Alzheimer’s disease is only a leading cause of
death in very high income countries. The other
guide for prominent world diseases, this study
finds that about 20% of nanomedicine
publications were directed towards a particular
illness. The rest of the nanomedicine research
was not directed towards fixing a specific
disease. Table 6 lists the top researched diseases
in nanomedicine. High income country diseases
are illnesses like Alzheimer’s and diabetes while
low income country diseases are diarrheal
diseases, HIV/AIDS, tuberculosis, malaria and
neonatal infections/deaths from prematurity.
Common to both groups are cancer, heart
disease, cerebrovascular disease, respiratory
infection and chronic obstructive pulmonary
disease (COPD).   
The disease with the most research
publications in both WoS and PubMed is cancer.
In both databases cancer accounts for 16% of
all nanomedicine publications and about 75%
of the directed nanomedicine research. Cancer
is major cause of death, but the strong emphasis
on cancer over exaggerates its burden of disease.
It is estimated that cancer causes 12% of deaths
worldwide (World Health Organization, 2008).
For men the most deadly type of cancer is lung
and trachea cancer while breast cancer is the
deadliest type of cancer for women.  Over the
past decade governments and foundations
invested a lot of money in cancer research.  For
example, in 2009, the National Cancer Institute
(NCI) disbursed $5 billion dollars for cancer
research; 12% of the funds went to breast cancer,
6% to prostate cancer and 5% to lung cancer
(“National Cancer Institute”, 2011).  The large
investment in cancer research likely drives the
emphasis on cancer in nanomedicine.  Table 7
lists the most researched cancers in
nanomedicine.  The publication profile closely
resembles that funding patterns of the NCI.  The
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Type of Cancer
breast cancer
prostate cancer
skin cancer
lung cancer
1630
494
567
484
WoS
749
354
307
291
PubMed
600
104
294
247
($ millions)
colon cancer
bladder cancer
...
Total cancer
217
...
69
12350
205
....
54
10083
264
...
26
5000
Table 7 Cancer Research in Web of Science (WoS) and PubMed
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“high income” diseases that receive a lot of
attention from nanomedicine are diabetes, colon
cancer and stomach cancer.
In contrast to very high income diseases, the
most researched diseases for low income are
diarrheal disease, HIV/AIDS, neonatal infections,
tuberculosis and malaria. Hepatitis, another
major nanomedicine research area, is not one
of the top killers in low income countries but
the disease disproportionately affects the poor
(see Table 6). 
The nanomedicine publication patterns from
low income countries are distinct from very high
income countries.  While very high income
countries conduct research on all the diseases,
nanomedicine research from low income
countries is focused on diseases of poverty like
malaria and tuberculosis; 78% of the
nanomedicine in WoS from low income countries
are about diseases of poverty. In comparison
only 16% of nanomedicine articles from very
high income countries deal with diseases of
poverty.  Therefore even though low income
countries produce far fewer nanomedicine
publications than very high income countries,
their research profiles are geared towards
diseases that affect their population.  
Another trend among low income countries
is that they collaborate more  than high income
countries; 78% of the nanomedicine articles
from low income countries in WoS were “north-
south” collaborations.  On the other hand a small
percentage of collaborations in very high income
countries were with the global south.  The data
suggests that low income countries rely on
collaboration with rich countries in order to
produce researched indexed in WoS or PubMed. 
Overall in WoS (Figure 2) about 86% of the
nanomedicine research impacts both rich and
middle/low income countries; 7% of the research
is directed towards problems of the rich and 7%
is directed towards problem of middle/low
income countries.  A significant amount of the
research that will help both rich and poor relates
to cancer; 88% of the “pro-poor” research is
cancer research.  Even when cancer is removed
from the dataset, the data still shows that
nanomedicine research is balanced between
country income groups (Figure 3)1 .  Finally,  when
the publication profile is examined based on
population, there is not any inequality in
nanomedicine research.  About 5.7 billion or 82%
of the world’s population live in middle/low
income countries and 93% of nanomedicine
research will benefit this population. Most of
that benefits the poor is about cancer, however
there is significant research on malaria,
tuberculosis and HIV/AIDS. 
4.4 Inequality in Disease Burden
The top ten leading causes of death
accounted for 30 million deaths or 50% in 2004.
The total amount of directed nanomedicine
research on these deadly diseases is 10% in WoS
and 19% in PubMed. Hence diseases that account
for half the world’s death receive between 10%
and 19% of research.  This suggests that is a
20/50 gap: Less than 20% of nanomedicine
research goes to solving problems that account
for 50% of the global disease burden.  Though
this statistic shows that there is inequality in
nanomedicine research, it is not as bad as a
10/90 gap.  
Some diseases kill relatively few people each
year but they receive a lot of attention from
researchers; these diseases are over researched.
On the other hand some diseases are under
researched; these diseases have high mortality
rates yet are not heavily researched. Figure 4
shows the disease research to death ratio of
several diseases.  If the disease to death ratio is
less than 1, then scientists are spending less
time researching the disease relative to its
mortality rate.  On the other hand, if the disease
to death ratio is greater than 1, then researchers
are spending more time studying a disease
compared to its mortality rate.  Six diseases,
diarrhea, COPD, lower respiratory disease,
cerebrovascular disease, heart disease, and
prematurity/low birth weight in infants receive
significantly less research than they deserve2.
On the other hand, cancer, hepatitis, Alzheimer’s,
Parkinson’s disease and arthritis receive more
attention than is warranted.  Hepatitis
publications are about 3% of all directed
nanomedicine research, but it only kills about
0.3% of the world’s population.  The disease ratio
to research ratio for the three major diseases of
poverty, tuberculosis, HIV/AIDS, and malaria are
not heavily skewed.  The research to death ratio
for these diseases range from 0.65% to 0.9%.
This shows that scientists are devoting sufficient
amount of attention to these diseases and that
overall there isn’t research inequality for these
diseases.  
Thomas S. Woodson
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1)   Note: WoS and PubMed have similar results so only graphics are shown
2)   Stomach cancer, which appears to have a low disease to death ratio was excluded from the list of understudied diseas. Even thought stomach cancer causes a lot of deaths 
and is not discussed in the literature, there is a lot of research on cancer in general
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Figure 4 Normalized ratio of the number of research articles to the number of people killed by that disease
High Income
Diseseas
Pop.=0.97 billion
Low and Middle
Income Diseases
Pop.= 5.54 billion
PubMed
High Income
Diseseas
Pop.=0.97 billion
Low and Middle
Income Diseases
Pop.= 5.54 billion
Ratio articles to deaths (WoS)
Ratio articles to death (PubMed)
5 Discussion
This paper gives a descriptive analysis of
nanomedicine research and classifies whether
there is inequality in the research.  Overall twenty
percent of all nanotechnology articles are related
to nanomedicine and in WoS the percent of
nanomedicine articles has grown over the past
10 years.  Nanomedicine is growing in
importance and scientists are developing new
medicines to address many of the world’s
diseases.  
This study has three hypotheses. The first
hypothesis is that nanomedicine is
predominantly conducted in very high income
countries.  The data supports this hypothesis.
About 77% of nanotechnology research is
conducted in very high income countries but
these countries only contain 15% of the world’s
population. However over the next few decades,
it is possible that the trend will change. Medium
income countries like China and India are
becoming world leaders in nanotechnology and
they are rivaling countries with very high
incomes in nanomedicine research.  
The second hypothesis is that there is a
disproportionate amount of nanotechnology
research conducted on diseases of very high
income countries.  There is no evidence to
support this hypothesis.  Scientists are doing
nanomedicine research on a variety of diseases
that affect both the rich and the poor.  Although
diseases of the rich like Alzheimer’s and breast
cancer receive the most attention, diseases like
tuberculosis, malaria and HIV/AIDS also receive
some attention from nanomedicine scientists.
The disease with the most nanomedicine
publications is cancer.  Cancer is a leader killer
in high income countries, but currently cancer
is not a top disease in middle and poor countries.
However as people in poor countries get richer
and have longer life expectancies, cancer will
become a more serious problem. 
The third hypothesis is that the majority of
nanomedicine research only addresses diseases
that kill relatively few people. This hypothesis
is partially confirmed. Several diseases like skin
cancer, hepatitis, breast cancer, Parkinson’s and
arthritis are over researched. These diseases
cause relative few deaths yet they receive a lot
of attention from scientists. Nevertheless there
are several diseases like diarrhea disease, COPD
and infant death due to prematurity and low
birth weight do not receive enough attention
from scientists. However there are many diseases
of poverty, like malaria, HIV/AIDS, and
tuberculosis that do receive enough attention
in relation to the number of people the diseases
kill. Moreover there is a 20/50 gap in
nanomedicine: less than 20% of nanomedicine
research goes to solving diseases that account
for 50% of deaths. 
There are several limitations to this study.
First the study uses Web of Science and PubMed
to quantify inequality in nanomedicine. Though
these databases are often used in bibliometric
studies they have small biases. These databases
tend to have a higher representation of English
journals and they tend to have more journals
from high income countries (UNESCO, 2005). As
a result, research from developing countries may
be under represented in the dataset. Also this
study cannot determine whether the articles
were discussing how nanotechnology can cure
diseases, cause more diseases or provide patients
with more access to nanomedicine. This is
especially significant when analyzing cancer.
Scientists study both how nanotechnology can
fight cancer (Ferrari, 2005) and how it could
potential cause cancer (Stern & McNeil, 2008).
As a result some of the nanomedicine papers
may focus on toxicology as opposed to fighting
cancer.  Finally many of the top “diseases” do
not have much overlap with nanomedicine. For
example, traffic accidents is the ninth leading
cause of death, and self-inflicted injuries is the
sixteenth leading cause of death. It is doubtful
that nanomedicine will impact those areas.  
From this study it is hard to conclude why
nanomedicine does not have large research
inequalities like those reported in other medical
fields. One potential cause is that research profile
is heavily influenced by funding agencies that
sponsor disease specific nanomedicine.  15% of
the WoS articles in the nanomedicine dataset
attribute a funding sponsor.  Most of the
sponsored research is attributed to large
government research funding organizations like
the USA National Institutes of Health (NIH).
Since cancer is a major focus area for the NIH,
scientists may be drawn to cancer research in
order to get research money. Other factors that
affect scientist motivations may like organization
structure and reward system (Fox, 1983).
This study is a first step in understanding
inequality in nanomedicine and adds to the
discussion on the 10-90 gap. It shows that
scientists are studying how emerging
technologies, like nanotechnology, can benefit
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the poor and that many of the inequality trends
that existed in research and technology are
changing. In the future scholars can add
information about whether nanomedicine
effects health inequality based on disability
adjusted life years (DALY). DALY’s is an alternative
measure of the burden of disease that captures
the disease burden based on the years of life
lost resulting from premature death and the
loss resulting from losing full quality of health
(World Health Organization, 2008). By studying
inequality with DALY we can understand the
effects of nanomedicine on non-fatal diseases.
Moreover, scholars need to understand why
nanomedicine is not following the pattern of
other medical research. Is there a reason that
nanomedicine is not following the same 10-90
gap that is apparent in other medical fields?  
Moral philosophies and belief systems view
inequality as bad for society (S. E. Cozzens, 2007).
Science and technology can play a crucial role
in diminishing inequality however science and
technology does not automatically reduce
inequality (Woodhouse & Sarewitz, 2007). If the
technology is not introduced correctly it can
lead to greater inequalities as seen in other areas
of medical technologies. The chemicals industry
plays a crucial role in nanomedicine. Although
it may not be directly involved in choosing the
research portfolio for researchers, the chemical
industry plays a big part of providing supplies,
equipment and expertise for the technology.
The research in nanomedicine will influence
where companies should operate and what type
of nanotechnology products it should offer to
consumers.  By understanding the research in
nanomedicine, the field will be able better
respond to customer demand.
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